prIME Decision Points in the Management of <em>EGFR</em>-Mutant NSCLC - priME Oncology
prIME Decision Points
prIME Decision Points

prIME Decision Points in the Management of EGFR-Mutant NSCLC

Not a member of My prIME? Join now for instant access.

prIME Decision Points in the Management of EGFR-Mutant NSCLC

View Activity
View Activity

Provider

This activity is provided by prIME Oncology.

Activity Date

RELEASE DATE
July 1, 2016

EXPIRATION DATE
July 2, 2017

Activity Overview

This CME-certified activity focuses on the management and treatment of patients diagnosed with EGFR-mutant non-small cell lung cancer (NSCLC) and includes clinical scenarios that mimic a patient receiving multiple lines of treatment. The case includes patient history, laboratory results, and options for next steps in treatment, while expert faculty provide commentary and insight.

Discussants

  • Suresh Ramalingam, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States
  • Heather Wakelee, MDStanford University
    Stanford, California, United States

Content Development

  • Rathi Pillai, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States

Topics

  • EGFR-mutant NSCLC
  • First-line treatment of EGFR-mutant NSCLC
  • Management of adverse events in EGFR-mutant NSCLC
  • Incorporation of biopsy into treatment decisions in EGFR-mutant NSCLC
  • Third generation tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC
  • Third generation TKI failure in EGFR-mutant NSCLC

Target Audience

This educational activity is specifically designed for medical oncologists, pulmonologists, pathologists, nurses, advanced practice professionals, and other healthcare professionals who manage and treat patients with lung cancer.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Select optimal treatment for EGFR-mutant NSCLC based on patient and disease characteristics, including molecular data
  • Differentiate toxicity profiles of EGFR TKIs and describe strategies for managing treatment-related adverse events in EGFR-mutant NSCLC
  • Evaluate current and emerging agents and treatment strategies for EGFR-mutant NSCLC

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

accme

prIME Oncology designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This educational activity is supported by a grant from Boehringer Ingelheim.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Pillai has disclosed that she has received consulting fees from Natera, Inc. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ramalingam has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Lilly, Merck, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wakelee has disclosed that she has received consulting fees from Novartis and Peregrine. She has also performed contracted research for Bristol-Myers Squibb, Celgene, Clovis, Lilly, Medimmune, Novartis, Pfizer, Roche/Genentech, and Xcovery. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sheila Waters, MSN (senior director clinical operations content reviewer/planner) – no relevant financial relationships
  • Briana Betz, PhD (clinical content reviewer/planner) – no relevant financial relationships
  • Christi Gray (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.